Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation
- 8 January 2008
- journal article
- Published by Springer Nature in JBIC Journal of Biological Inorganic Chemistry
- Vol. 13 (4) , 511-520
Abstract
Reaction of 3-pyridinehydroxamic acid and 4-pyridinehydroxamic acid (3-pyha and 4-pyha) with either [NBu4][RuCl4(dmso-S)2] or [(dmso)2H][RuCl4(dmso-S)2] (dmso is dimethyl sulfoxide) in acetone afforded three new ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes: [NBu4][trans-RuCl4(dmso-S)(4-pyha)]·CH3COCH3 (1), [3-pyhaH][trans-RuCl4(dmso-S)(3-pyha)] (2) and [4-pyhaH][trans-RuCl4(dmso-S)(4-pyha)] (3). The solid-state structure of [NBu4][trans-RuCl4(dmso-S)(4-pyha)]·CH3COCH3 (1) was determined by X-ray crystallography. 2 and 3 were pharmacologically evaluated for their in vitro cytotoxicity, their ability to inhibit cell invasion and their gelatinase activity. 2 and 3 were devoid of cytotoxicity against the cell lines tested. 2 inhibited invasion of the highly invasive MDA-MB-231 cells to a much greater extent than 3. Contrary to expectations, neither 2 nor 3 had any inhibitory effect on matrix metalloproteinase (MMP) production and/or activity and in fact 3 was found to enhance the production and/or activity of both MMP-2 and MMP-9.Keywords
This publication has 47 references indexed in Scilit:
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II) η6-Arene Imidazole ComplexesJournal of Medicinal Chemistry, 2006
- Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell InvasionThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Matrix metalloproteinases and tumor metastasisCancer and Metastasis Reviews, 2006
- KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development ? an overviewInt. Journal of Clinical Pharmacology and Therapeutics, 2005
- Synthesis, characterisation and speciation studies of heterobimetallic pyridinehydroxamate-bridged Pt(ii)/M(ii) complexes (M = Cu, Ni, Zn). Crystal structure of a novel heterobimetallic 3-pyridinehydroxamate-bridged Pt(ii)/Cu(ii) wave-like coordination polymerDalton Transactions, 2005
- Tuning of Redox Potentials for the Design of Ruthenium Anticancer Drugs − an Electrochemical Study of [trans-RuCl4L(DMSO)]- and [trans-RuCl4L2]- Complexes, where L = Imidazole, 1,2,4-Triazole, IndazoleInorganic Chemistry, 2004
- Synthesis and Chemical−Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine)Journal of Medicinal Chemistry, 2004
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D Structural Biology, 1994
- Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexesInorganic Chemistry, 1991